Belumosudil Production Cost Reports

The report provides a detailed analysis essential for establishing a belumosudil production plant. It encompasses all critical aspects necessary for belumosudil production, including the cost of belumosudil production, belumosudil plant cost, belumosudil production costs, and the overall belumosudil production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a belumosudil production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Belumosudil is a small-molecule drug that is mainly used in the medical field for the treatment of chronic graft-versus-host disease (cGVHD). It works by inhibiting a specific enzyme called ROCK2, which plays a role in inflammation and fibrosis. It helps reduce tissue damage and improves symptoms in patients who have not responded well to other therapies. It is mainly used as an oral medication for the treatment of chronic graft-versus-host disease (cGVHD), which is a condition that can occur after a stem cell or bone marrow transplant. It is primarily used in hospitals and speciality clinics as part of advanced transplant care, especially for patients who do not respond well to standard therapies. It is also utilised in combination therapies with drugs like ruxolitinib to improve outcomes in tough cGVHD cases. It is often used in managing immune-related complications and improving long-term outcomes after transplantation. In addition, it is used in pharmaceutical research for studying new treatments for immune disorders and fibrotic diseases.

The primary factor that drives the market for belumosudil is its demand as a targeted therapeutic option in modern medicine for controlling chronic transplant-related conditions. Its application in the treatment of chronic graft-versus-host disease in patients aged twelve years and older who failed prior lines of systemic therapy also fuels its demand in the pharmaceutical industry. Its application as an oral drug to control inflammation and fibrosis in specific medical conditions also drives its demand in the medical and healthcare sectors. Its demand as a valuable drug in the medical research industry to study its effects in other immune-related and fibrotic disorders further promotes its market growth. The rising number of hematopoietic stem cell transplants worldwide, along with growing awareness about post-transplant complications, continues to boost its demand in hospitals and speciality clinics. Manufacturing capabilities, supplier reliability, cold-chain distribution systems, and compliance with safety guidelines also play a significant role in shaping its global procurement and supply. Moreover, industrial belumosudil procurement is also influenced by factors such as the cost and availability of active pharmaceutical ingredients, strict regulatory requirements, patent protection, and quality assurance standards.

Raw Material for Belumosudil Production

According to the belumosudil production plant project report, the major raw materials for belumosudil production include bromoacetyl bromide, isopropylamine, methyl 3-hydroxybenzoate, oxalyl chloride, 2-aminobenzamide, and 5-aminoindolazole.

Production Process of Belumosudil

The extensive belumosudil production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of belumosudil begins with the reaction of bromoacetyl bromide and isopropylamine to form an intermediate amide, which is then coupled with methyl 3-hydroxybenzoate to create an ether compound. Further, this intermediate undergoes saponification to form a carboxylic acid, which is converted to an acid chloride using oxalyl chloride. Then, the acid chloride is reacted with 2-aminobenzamide to form a new amide, which is cyclized under alkaline conditions to form a quinazolinone ring. This structure is chlorinated to produce 4-chloroquinazoline, which undergoes a substitution reaction with 5-aminoindolazole, resulting in the formation of belumosudil as the final product.

Belumosudil is a selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor that belongs to the class of serine/threonine kinase inhibitors. It appears as a solid powder and is stored at -20 degrees Celsius to maintain stability. The molecular formula of the compound is C26H24N6O2, and its molar mass is 452.51 g/mol. It has a density of approximately 1.3 g/cm³, and its boiling point is approximately 682.6 degrees Celsius at 760 mmHg. The flash point of the compound is around 366.6 degrees Celsius. It is insoluble in water and ethanol but is freely soluble in DMSO. The compound is marketed under the brand name Rezurock. It is known to carry embryo-fetal toxicity and may cause significant harm to a developing fetus. The most common side effects associated with the compound include infection, fatigue, nausea, diarrhoea, shortness of breath, and high blood pressure. It is recommended that patients of reproductive potential use effective contraception during treatment and for at least one week after the last dose.